Table 5. Response to treatment for patients with stage III–IV disease.
| CIP (n=97) | CEP (n=94) | |
|---|---|---|
| Response | No. (%) | No. (%) |
| Complete response | 41 (48) | 45 (52) |
| Clinical | 12 (14) | 14 (16) |
| Pathological | 29 (34) | 31 (36) |
| Partial response | 32 (37) | 33 (38) |
| Clinical | 4 (5) | 8 (9) |
| Pathological | 28 (33) | 25 (29) |
| Stable disease | 10 (12) | 7 (8) |
| Clinical | 3 (3) | 1 (1) |
| Pathological | 7 (8) | 6 (7) |
| Progressive disease | 3 (3) | 1 (1) |
| Clinical | 2 (2) | 0 |
| Pathological | 1 (1) | 1 (1) |
| Inevaluablea | 11 | 8 |
Abbreviations: CEP=cisplatin/paclitaxel/epirubicin; CIP=cisplatin/paclitaxel/ifosfamide.
a
Response was not evaluable in patients without evidence of disease after the first surgery and negative CA125.